small molecule

MULPLETA

LUSUTROMBOPAG

Loss of exclusivitySeptember 2031latest FDA-listed patent expiry
CompanyVANCOCIN ITALIA SRL

Drug detail

Brand nameMULPLETA
Active ingredientLUSUTROMBOPAG
Strength3MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2018
Marketing statusRX

Listed patents

PatentExpiresType
9427402September 2031product
8530668January 2030substance, product
8889722July 2028substance, product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

MULPLETA patent cliff — loss of exclusivity September 2031 | CliffBio